Insights

Strategic asset moves Nabriva recently sold Contepo North American rights to Meitheal Pharmaceuticals, indicating active divestiture or portfolio optimization. Sales teams should monitor ongoing licensing and distribution opportunities for Contepo alternatives in other regions and explore co-promotion or reformulation deals with partners in markets retaining the asset.

Expanded Xenleta opportunities Xenleta has been launched and broadened through distribution agreements and in-house promotion efforts, with prior regional asset divestments in Asia. There remains room to target international partners or distributors for additional geographies, as well as hospital systems pursuing ceftriaxone-alternative options for cUTI or other sinergistic indications.

Clinical pipeline leverage Contepo and Xenleta together position Nabriva in complicated urinary tract infections and acute bacterial indications. BD teams should identify hospital networks and ID specialists seeking first-in-class or novel epoxide/ fosfomycin-based therapies, offering bundled solutions, training, and investigator-sponsored studies.

Financing and partnerships Past collaborations with Merck and Er-Kim show a history of strategic alliances. Potential growth through co-development, milestone-based partnerships, or capacity-sharing arrangements could unlock additional revenue, particularly in regions where Nabriva lacks commercial presence.

Operational footprint With headquarters in Dublin and operations in Vienna and King of Prussia, Nabriva’s multi-country footprint allows cross-border distribution and regional supply-chain partnerships. Target opportunities include regional distributors, CROs, and hospital groups seeking reliable antibiotic supply and support services across Europe and North America.

Similar companies to Nabriva Therapeutics plc

Nabriva Therapeutics plc Tech Stack

Nabriva Therapeutics plc uses 8 technology products and services including UserWay, Amazon Web Services, Drupal, and more. Explore Nabriva Therapeutics plc's tech stack below.

Media & News

Nabriva Therapeutics plc's Email Address Formats

Nabriva Therapeutics plc uses at least 2 email formats:
Nabriva Therapeutics plc Email FormatsExamplePercentage
First.Last@nabriva.comJohn.Doe@nabriva.com
87%
Last@nabriva.comDoe@nabriva.com
13%

Frequently Asked Questions

What is Nabriva Therapeutics plc's phone number?

Minus sign iconPlus sign icon
You can contact Nabriva Therapeutics plc's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Nabriva Therapeutics plc's stock symbol?

Minus sign iconPlus sign icon
Nabriva Therapeutics plc is a publicly traded company; the company's stock symbol is NBRVF.

What is Nabriva Therapeutics plc's official website and social media links?

Minus sign iconPlus sign icon
Nabriva Therapeutics plc's official website is nabriva.com and has social profiles on LinkedIn.

How much revenue does Nabriva Therapeutics plc generate?

Minus sign iconPlus sign icon
As of October 2026, Nabriva Therapeutics plc's annual revenue is estimated to be $10M - $25M.

What is Nabriva Therapeutics plc's SIC code and NAICS code?

Minus sign iconPlus sign icon
Nabriva Therapeutics plc's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Nabriva Therapeutics plc have currently?

Minus sign iconPlus sign icon
As of October 2026, Nabriva Therapeutics plc has approximately 23 employees across 2 continents, including North America and Europe. Key team members include Chief Executive Officer, Nabriva Therapeutics: J. J., Chief Medical Officer: D. M. and Clinical Trial Manager: S. K. Explore Nabriva Therapeutics plc's employee directory with LeadIQ.

What industry does Nabriva Therapeutics plc belong to?

Minus sign iconPlus sign icon
Nabriva Therapeutics plc operates in the Biotechnology Research industry.

What technology does Nabriva Therapeutics plc use?

Minus sign iconPlus sign icon
Nabriva Therapeutics plc's tech stack includes UserWay, Amazon Web Services, Drupal, Osano, Microsoft Azure, New Relic, Adobe Tag Manager and YouTube.

What is Nabriva Therapeutics plc's email format?

Minus sign iconPlus sign icon
Nabriva Therapeutics plc's email format typically follows the pattern of First.Last@nabriva.com. Find more Nabriva Therapeutics plc email formats with LeadIQ.

When was Nabriva Therapeutics plc founded?

Minus sign iconPlus sign icon
Nabriva Therapeutics plc was founded in 2006.
Nabriva Therapeutics plc logo

Nabriva Therapeutics plc

Biotechnology ResearchDublin, Ireland11-50 Employees

Nabriva Therapeutics plc is a commercial-stage biotechnology company focused on developing novel antibiotics to treat serious infections. It is headquartered in Dublin, Ireland, with offices and laboratories in Vienna, Austria and King of Prussia, Pennsylvania, and additional locations in San Diego, California, United States. The company markets Xenleta (lefamulin), approved by the FDA for oral and intravenous use, and CONTEPO (fosfomycin) for injection, for which a US NDA has been submitted for complicated urinary tract infections including acute pyelonephritis. Recent strategic actions include the sale of Contepo assets to Meitheal Pharmaceuticals in July 2024 and prior asset divestitures such as Xenleta assets transferred to Sumitomo Pharma in 2023, with an earlier Merck collaboration in 2020 to market SIVEXTRO. The organization employs between 11 and 50 people.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
NBRVF
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2006
Employees
11-50

Section iconFunding & Financials

  • $10M - $25M

    Nabriva Therapeutics plc's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.